NEFL and Alzheimer disease: When combining the two biomarkers with the age+sex+APOE4 panel (combination panel: age+sex+APOE4+GFAP+NfL), the AUC of HC vs. AD reached 91.6% (95%CI = 0.85–0.98, p < 0.001, Figure 3A), AUC of HC vs. MCI 81.7% (95%CI = 0.73–0.90, p < 0.01, Figure 3B) and for amyloid positivity 87.5% (95%CI = 0.73–0.96, p < 0.05, Figure 3D), therefore, significantly outperforming the age+sex+APOE4 panel alone.